Prime Highlights
- Zuellig Pharma has expanded its partnership with Danish drugmaker Lundbeck to improve access to brain health medicines across Asia.
- The collaboration highlights Zuellig Pharma’s continued focus on strengthening healthcare services and supporting mental health needs in the region.
Key Facts
- Under the expanded agreement, Zuellig Pharma will help market and sell Lundbeck medicines such as Lexapro®, Brintellix®, and Cipralex®.
- The partnership covers Indonesia, Malaysia, the Philippines and Singapore, building on an existing distribution arrangement.
Background:
Zuellig Pharma has expanded its partnership with Danish drugmaker Lundbeck to improve access to brain health medicines in Asia.
Under the new agreement, Zuellig Pharma will help market and sell key medicines, including Lexapro®, Brintellix® and Cipralex®, across Indonesia, Malaysia, the Philippines and Singapore. It has also been extended to include Taiwan, increasing Lundbeck’s presence in the region.
As part of the agreement, Zuellig Pharma will deliver comprehensive end-to-end commercialization support for Lundbeck’s product portfolio. This includes marketing and commercial execution, market access strategies, distribution and supply chain management, medical information services, regulatory and quality support, as well as pharmacovigilance. The move is intended to ensure patients continue to have reliable access to important medicines for brain and mental health conditions.
The partnership is supported by Zuellig Pharma’s wide regional network and strong understanding of local markets. Operating across 18 Asian markets, the company helps connect drug makers with healthcare providers so medicines are delivered safely and on time.
Commenting on the development, Zuellig Pharma Chief Executive Officer John Graham said the company values its long-standing relationship with Lundbeck and remains focused on improving access to brain health treatments across Asia. He added that Zuellig Pharma’s deep understanding of local regulatory environments and healthcare systems will help support continuity of care for patients throughout the region.
Founded more than 100 years ago, Zuellig Pharma has grown into a multibillion-dollar healthcare company. It supports more than 200,000 medical facilities and works with over 450 clients. The expanded partnership highlights Zuellig Pharma’s focus on improving healthcare and mental health access across Asia.
